Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6419.0000 -43.50 (-0.67%)
NSE Nov 21, 2025 10:07 AM
Volume: 23,232
 

6419.00
-0.67%
BOB Capital Markets Ltd.
LICI: Solid quarter; valuations overdone cut to HOLD. ALKEM: Good quarter; cut to SELL on stretched valuations. Monthly Chartbook: Fiscal consolidation to hold key. PWGR: In-line quarter, FY25 capex hiked; maintain BUY. TATACONS: Strong run continues. DIVI: Healthy margin recovery, heady valuations. TPW: Dull quarter; high valuations maintain HOLD. ESCORTS: Weakness persists - maintain SELL. TRCL: Tepid quarter, high capex overhang retain SELL. Metals & Mining: Ferrous read-across: Steel recovery in CY24 - ArcelorMittal
Deven Choksey increased Accumulate price target of Divi's Laboratories Ltd. to 6795.0 on 20 Nov, 2025.
More from Divi's Laboratories Ltd.
Recommended